Kenmore, Washington-based Echolight Medical LLC has entered into a multi-year contract with the largest member-driven health care performance improvement company with $100 billion in annual purchasing volume—Irving, Texas-based Vizient Inc. Echolight will be supplying its Radiofrequency Echographic Multi Spectrometry (REMS) technology to Vizient members at contract pricing.
Bone Density Tech Coming to Vizient Members
Echolight Medical’s bone density systems are indicated for “bone density and quality assessment at the lumbar vertebrae and the femoral neck” with results in minutes.
Echolight Medical Vice President of Marketing Gina Raebel spoke with OTW about what sets REMS apart from its competitors. Raebel told OTW, “REMS is a more sensitive, more accurate technology than DXA [Dual-energy X-ray absorptiometry], but it’s also portable and without radiation, so we’re not necessarily competing directly with DXA, because we’re more focused on new opportunities at the point-of-care, such as with general practitioners, orthopedics, rheumatologists, endocrinologists, women’s health specialists, and others that might not typically be known for having a DXA in-house.”
Contracted pricing with Vizient will help to make the technology available throughout the U.S. It represents an important step in Echolight Medical’s goal of continual growth.
Raebel discussed Echolight Medical’s growth efforts with OTW, saying, “There’s a busy year ahead, not limited to: formalizing the advisory board and continuing to grow the network of key advocates throughout the country; targeted growth efforts in North America, with emphasis in the southeast, on the West Coast, and in Canada; launching the North American web presence (new website, social media, etc.); and executing our government relations efforts to educate lawmakers on the effectiveness and opportunities provided by REMS.”

Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.